Previously, we found that MRFs (myogenic regulatory factors) regulated the expression of PGC-1α (peroxisome-proliferatoractivated receptor γ co-activator 1α) by targeting a short region, from nt − 49 to + 2 adjacent to the transcription initiation site, that contained two E-boxes. However, only the E2-box had significant affinity for MRFs, and the E1-box was predicted to be the target of Bhlhe40 (basic helix-loop-helix family, member e40, also known as Stra13, Bhlhb2, DEC1 and Sharp2), a transcriptional repressor implicated in the regulation of several physiological processes. In the present study, by using EMSA (electrophoresis mobility-shift assay), we confirmed that Bhlhe40 targeted the E1-box and formed a complex with the basic helix-loop-helix transcription factor MyoD (myogenic differentiation factor D) on the PGC-1α core promoter. We demonstrate that Bhlhe40 binds to the promoters of PGC-1α and myogenic genes in vivo and that Bhlhe40 represses the MyoD-mediated transactivation of these promoters. Furthermore, we found that this repression could be relieved by P/CAF (p300/CBP-associated factor) in a dosedependent manner, but not by CBP [CREB (cAMP-responseelement-binding protein)-binding protein]. Bhlhe40 interacted with P/CAF and this interaction disrupted the interaction between P/CAF and MyoD. These results suggest that Bhlhe40 functions as a repressor of MyoD by binding to adjacent E-boxes and sequestering P/CAF from MyoD.
INTRODUCTION
Trunk skeletal muscle cells are derived from axial somitic precursor cells during early embryogenesis [1] . These somitic precursor cells are committed to the myogenic lineage only once they start expressing a myogenic bHLH (basic helix-loop-helix) transcription factor, either MyoD (myogenic differentiation factor D) or Myf5 (myogenic factor 5) [2] . Their terminal differentiation is dictated by the function of the myogenic bHLH protein family, called MRFs (myogenic regulatory factors), including MyoD, Myf5, Myog (myogenin) and Myf6 (myogenic factor 6, also known as MRF4). Myogenic bHLH proteins can activate the expression of further transcription factors from the MEF2 (myocyte enhancer factor 2) family to promote myoblasts to enter terminal differentiation [3] . Together, myogenic bHLH and MEF2 proteins regulate the terminal differentiation of myoblasts into multinucleated myotubes by activating musclespecific contractile genes and genes that promote cell-cycle exit, such as p21cip1 (cyclin-dependent kinase inhibitor 1A) and p27kip1 (cyclin-dependent kinase inhibitor 1B) [4, 5] .
Myogenic bHLH proteins require the facilitation of transcriptional co-activators, such as p300/CBP [CREB (cAMPresponse-element-binding protein)-binding protein], and P/CAF (p300/CBP-associated factor) to activate their myogenic target genes [6, 7] . Both p300/CBP and P/CAF are HAT (histone acetylase)-containing co-activators that can potentiate transactivation of DNA-binding transcription factors by acetylating lysine residues of histone proteins. Their HAT activities are essential for the myogenic terminal differentiation and each is required for the activation of different set of myogenic genes [8, 9] . Acetylation of MyoD by P/CAF enhances its affinity for DNA, which is necessary for the execution of the muscle differentiation programme [10] .
Recently it has been shown that over-expression of PGC-1α (peroxisome-proliferator-activated receptor γ co-activator-1α), a transcriptional co-activator, can promote the switch from anaerobic glycolysis to oxidative metabolism and thus increases the energy output [11, 12] . PGC-1α is highly expressed in tissues, such as heart, skeletal muscle, and brown fat that requires high-energy metabolism [13] . In muscle, PGC-1α is preferentially expressed in slow-twitch fibres, which are rich in mitochondria and employ oxidative metabolism to give a stable and constant ATP supply [14] . Since its identification, PGC-1α has been found to co-activate many nuclear hormone receptors, including TR (thyroid hormone receptor), ER (oestrogen receptor) and GR (glucocorticoid receptor) [13, [15] [16] [17] [18] . After the initial identification of PGC-1α, two other related genes, PGC-1β and PRC (PGC-1 related co-activator), were also identified based on their sequence homology with PGC-1α [19, 20] . These three genes form a small unique gene family of co-activators that play critical roles in metabolic homoeostasis in homoeotherms. Although the genes are largely expressed in tissues with a large energy requirement, the relative expression level among these tissues is not identical. For example, PRC is more highly expressed Abbreviations used: bHLH, basic helix-loop-helix; Bhlhe40, basic helix-loop-helix family, member e40; CBP, CREB-binding protein; ChIP, chromatin immunoprecipitation; CMB, confluent C2C12 myoblasts; CREB, cAMP-response-element-binding protein; DM1, cells in differentiation medium for one day; DM5, cells in differentiation medium for five days; DMEM, Dulbecco's modified Eagle's medium; DTT, dithiothreitol; EMSA, electrophoresis mobility-shift assay; FOXO1, forkhead box protein O1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GFP, green fluorescent protein; GST, glutathione transferase; HAT, histone acetylase; HDAC, histone deacetylase; MBP, maltose-binding protein; MCK, muscle creatin kinase; MEF2, myocyte enhancer factor 2; MHC, myosin heavy chain; MRF, myogenic regulatory factor; MT, myotube; Myf5, myogenic factor 5; MyoD, myogenic differentiation factor D; Myog, myogenin; NP40, Nonidet P40; P/CAF, p300/CBP-associated factor; p21cip1, cyclin-dependent kinase inhibitor 1A; PGC, peroxisomeproliferator-activated receptor γ co-activator; PMB, proliferating myoblast; PNK, polynucleotide kinase; PRC, PGC-1 related co-activator; RT-PCR, reverse transcription-PCR. 1 Both authors contributed equally to this work. 2 To whom correspondence should be addressed (email slchen@cc.ncu.edu.tw).
in skeletal muscle [13] , but PGC-1α and PGC-1β are more highly expressed in brown fat adipocytes [19, 20] . The differential expression pattern of this gene family during embryogenesis has yet to be established, as has whether they play any role in the establishment of these tissues during early organogenesis. Previously, we found that the expression of PGC-1α was regulated by all the myogenic bHLH proteins, especially MyoD and Myog [21] . These transcription factors activated PGC-1α transcription by targeting a short region (from nt − 49 to + 2) adjacent to the transcription initiation site that contained two putative E-boxes. However, only one site, the E2-box, showed significant affinity to myogenic bHLH proteins [21] . Using bioinformatic tools, we predicted that the E1-box was a target of the transcriptional repressor, Bhlhe40 (basic helix-loop-helix family, member e40; also known as Stra13, Bhlhb2, DEC1 and Sharp2). As the two E-boxes were situated close together, we decided to investigate how Bhlhe40 and the myogenic bHLH proteins might co-operate with each other in order to regulate the expression of PGC-1α.
Bhlhe40 is a transcriptional repressor that has been implicated in the regulation of cell differentiation, tumorigenesis, peripheral circadian output and response to hypoxia [22] [23] [24] [25] [26] . It is ubiquitously expressed in most tissues but shows especially strong expression in both human and mouse skeletal muscle [27, 28] . Although the Bhlhe40 sequence shows a high degree of homology to members of the E-class of bHLH family, Bhlhe40 binds to the B-class E-box (CACGTG) as a homodimer, rather than the N-box (CACGCG) as the other E-class members usually do [29] . Bhlhe40 also lacks the WRPW motif found in the E-class members, which is responsible for recruitment of the co-repressor Groucho [30] . Instead, it represses transcription through HDAC (histone deacetylase)-dependent and -independent mechanisms [31] . This repressive activity is mediated by the three α-helices located in the C-terminus; these directly interact with HDAC1 and the general transcription factor TFIIB (transcription factor II B) in the transcriptional machinery [30] . During embryogenesis, Bhlhe40 is expressed in neuroectoderm and in some mesodermand endoderm-derived tissues. Bhlhe40 expression is inducible by retinoic acid treatment in the P19 embryonic carcinoma cell line, and its over-expression in the same cells promotes neuronal differentiation, but suppresses endodermal and mesodermal differentiation [30] . It has been shown that Bhlhe40 suppress adipogenesis by inhibiting PPARγ 2 (peroxisome proliferatoractivated receptor γ isoform 2) expression [32] . Whether the same mechanism is employed in the repression of myogenic differentiation is currently unknown.
In the present study, we examine Bhlhe40-mediated regulation of PGC-1α expression during myogenesis and then further define the mechanism employed by Bhlhe40 to repress transcription. By using transfection assays and EMSA (electrophoresis mobilityshift assay), we confirmed the bioinformatic prediction that Bhlhe40 targets the E1-box of the PGC-1α promoter and that it also represses MyoD-mediated activation of the PRC and Myog promoters and the 4RE-TK promoter construct [containing 4 Eboxes placed upstream to the TK (thymidine kinase) promoter]. We also show Bhlhe40-mediated repression can be relieved by P/CAF, in a dose-dependent manner, but not by CBP. Our results suggest that Bhlhe40 functions as a repressor of MyoD by binding to adjacent E-boxes and by sequestering P/CAF from MyoD.
EXPERIMENTAL

Plasmids
Mouse PGC-1α, -1β and PRC promoters were amplified from mouse genomic DNA using nested PCR and cloned into the KpnI and XhoI (for PGC-1α and PGC-1β) or the SmaI (for PRC) sites of pGL3-basic vector (Promega). The cloned genomic regions are nt − 3229 to + 22, − 3329 to + 140 and − 3350 to + 362 for PGC-1α, β and PRC promoters respectively, relative to the transcriptional initiation site. The Bhlhe40 coding region was amplified from mouse cDNA. The process of RNA extraction and reverse transcription was the same as those described in the quantitative real-time RT-PCR (reverse transcription-PCR) section below. The amplified Bhlhe40 fragment was cloned into the yTA PCR cloning vector (Yeastern Biotech) before being subcloned into the EcoRI and XbaI sites of the pCDNA3.0 vector (Invitrogen) to make the mammalian expression construct. For the bacterial expression of the MBP (maltose binding protein)-Bhlhe40 fusion protein, Bhlhe40 cDNA was released from the yTA vector by EcoRI/SalI digestion and inserted into the same sites on the pMAL-C2X vector (a gift from Dr Chien C. Wang, Department of Life Sciences, National Central University, Taiwan). For all cloning protocols, the number of amplification cycles of each PCR was fewer than 25 to reduce the PCRrelated error rate. All the constructs were sequenced to ensure their sequence integrity. To construct the MBP-P/CAF fusion protein expressing vector, P/CAF cDNA was released from pCMX-P/CAF vector (a gift from Dr Yoshihiro Nakatani, Harvard Medical School, Boston, MA 02115, U.S.A.) by XbaI/NheI digestion and inserted into the HindIII (blunted) site of the pMAL-C2X vector. The pCDNA3.1-based MRF expression vectors and reporter constructs (in pGL3-basic) driven by myogenic gene promoters have been described previously in [21] . The pCDNA-GFP (green fluorescent protein) vector was a gift from Dr W. Seller, Dana-Faber Cancer Institute, Harvard Medical School, Boston, MA 02115, U.S.A.
Quantitative real-time RT-PCR
Total RNA was extracted from the myoblasts, myotubes, and muscle tissue using TRIzol ® (Invitrogen) according to the manufacturer's instructions. Then, the first strand of cDNA was synthesized using the Superscript III kit (Invitrogen) for RT-PCR according to the manufacturer's protocol. Briefly, total RNA (2 μg) was denatured at 65
• C for 5 min in the presence of 0.5 μg oligo(dT) and 1 mM dNTPs. After chilling on ice for at least 1 min, reverse transcription was allowed to proceed at 25
• C for 5 min in the presence of 1× first-strand buffer, 5 mM DTT (dithiothreitol), and 40 units of RNase inhibitor. Then, the reaction was allowed to proceed at 50
• C for another 60 min. The reaction was stoppped by heat inactivation at 70
• C for 10 min. Quantitative real-time PCR was performed in a 25 μl reaction mixture containing 5 μM forward and reverse primers, 1× SYBR Green reaction mix (Applied Biosystems) and various amounts of template. The reaction was performed with a preliminary denaturing step of 10 min at 95
• C, followed by 40 cycles of: 95
• C for 15 s, 60
• C for 1 min and 72
• C for 30 s. Various concentrations of template were assessed to make sure there was linear amplification of PCR products and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as internal control for levels of mRNA expression. The primer sets are listed in Table 1 . All the reactions were performed in ABI 7300 sequence detection system (Applied Biosystems). The expression level of each gene was first normalized to that of Gapdh. Normalized expression level, designated Ct, at PMB (proliferating myoblast) stage or in gastrocnemius muscle was arbitrarily set as 1. The relative expression level of each gene at CMB (confluent C2C12 myoblasts) and MT (myotube) stages and in soleus muscle was the calculated as 2 − Ct , where Ct is the change in Ct. 
Cell culture and transient transfection assay
Proliferating C2C12 (a mouse myoblast cell line) and 10T1/2 (a mouse embryo cell line) cells were cultured in DMEM (Dulbecco's modified Eagle's medium) supplemented with 20 % or 10 % (v/v) fetal calf serum respectively. All cells were kept at low confluence to prevent spontaneous differentiation. To induce terminal differentiation, the culture medium of confluent C2C12 myoblasts was changed to DMEM containing 2 % (v/v) horse serum to reduce the mitogen concentration in the medium. C2C12 normally started to differentiate 48-72 h after serum withdrawal. For transient transfection, aliquots of plasmid DNA (0.67 μg reporter and 0.16 μg of each expression vector) were added to 50 μl 1× Hepes buffer (20 mM Hepes, pH 7.0, containing 187 mM NaCl, 5 mM KCl, 0.7 mM Na 2 HPO 4 and 5.5 mM dextrose) in 1.5 ml tubes. Lipofectamine (Life Technologies) in 50 μl 1× Hepes buffer was then added so that the final ratio was 5:1 (w/w) Lipofectamine/DNA. The mixture was incubated at room temperature (25
• C) for 10-15 min to allow the DNA and liposome complex to form. Aliquots (1 ml) of culture medium were then added to each tube and mixed by inverting. This medium, containing the DNA-liposome complex, was then transferred to 10T1/2 cells grown on 12-well plates in triplicates and the transfection was allowed to proceed overnight after which the medium was replaced by fresh medium. Cells were harvested 24-48 h after transfection with repeated freeze and thaw cycles in lysis buffer [50 mM Tris/HCl, pH 8.1, containing 150 mM NaCl, 0.1 % SDS, 1 % (v/v) Triton-X 100 and 1× protease inhibitor (Sigma-Aldrich)]. Aliquots of total lysate (100 μl) were injected into a Clarity 2 luminometer (Bio-Tek) to determine their luciferase activity. All luciferase activities were normalized to that of pRL-TK control Renilla luciferase reporter vector (Promega; 1 μg), which was included in each reaction to serve as a transfection efficiency control. • C for at least 3.5 h. Signals on the gels were viewed by autoradiography. Antibody (0.5 μg) against cognate transcription factors was included in the binding reaction to verify the identity of factors in the retained bands on the gel.
GST (glutathione transferase) and MBP pulldown assays
GST-and MBP-fusion proteins were expressed in Escherichia coli strain BL21 and purified by affinity chromatography using glutathione-agarose (Pharmacia) and MBP-agarose (New England Biolabs) beads respectively. The GST-and MBP-fusion proteins were analysed by SDS/PAGE (10 % gels) to examine their integrity and to normalize the protein levels. Proteins labelled with [ 35 S]-methionine or cysteine were produced by using the TnT ® -coupled system (Promega). In vitro binding assays were performed with 3-6 μl [
35 S]-labelled proteins and 300-500 ng GST-or MBP-fusion proteins adsorbed on the agarose beads in 500 μl HEMG buffer [40 mM Hepes, pH 7.8, containing 0.2 mM EDTA, 100 mM KCl, 0.1 % NP40 (Nonidet P40), 1.5 mM DTT and 10 % (v/v) glycerol] freshly supplemented with 1 % BSA and 1× protease inhibitor mix (Sigma-Aldrich). The reaction was allowed to proceed for 2 h at room temperature, or overnight at 4
• C, with gentle rocking. The affinity beads were collected by centrifugation at 1700 g for 2 min and washed with 1 ml HEMG buffer. The wash step was repeated four times and the beads were air-dried before the addition of 2× Laemmli SDS sample buffer [0.125 M Tris/HCl, pH 6.8, containing 4 % (w/v) SDS, 20 % glycerol, 10 % (v/v) 2-mercaptoethanol] to elute bound proteins. Eluted proteins were resolved by SDS/PAGE (10 % gels) and signals visualized with autoradiography.
ChiP (chromatin immunoprecipitation) assay
CMB and cells kept in differentiation medium for one and five days (called DM1 and DM5 cells respectively) were washed several times with PBS before being fixed in 1 % (w/v) formaldehyde for 20 min at 25
• C. Then, cells were washed twice with cold PBS, followed by incubation in PBS containing 125 mM glycine for 15 min before being scraped off in PBS containing 2 mM EDTA. Cells were spun at 420 g for 5 min at 4
• C, and then washed twice with ice-cold PBS. The pellet was re-suspended in 250 μl lysis buffer and sonicated at least five times for 30 s with The primer sequence for each gene was listed in table I. * P < 0.05 ** P < 0.01 compared with the of PMB stage. Results are the means + − S.D. for at least three independent experiments. For the amplification of each gene, PCR was started with a cDNA template equivalent to 25 ng of total RNA. PCR controls using the equivalent amount of total RNA or no template were run simultaneously to examine the degree of genomic DNA contamination. All primer sets were designed to cross at least one intron so that the amplicon of their genomic DNA targets are significantly different in size from that of their cDNA targets. Only samples without detectable genomic DNA contamination were further analysed.
a 140-150 W pulse followed by a 30 s rest interval. The lysate was spin at 17 900 g for 10 min at 4
• C and the supernatant was transferred to a new tube. Then, Protein A/G agarose (Pharmacia, 80 μl) was added to the supernatant and the mixture was incubated at 4
• C for 20 min before centrifugation at 3800 g for 5-10 min at 4
• C to clear the solution. The supernatant was transferred to a new tube, into which 1 μg specific antibody was added. The binding was allowed to proceed at 4
• C overnight. Protein A/G agarose (80 μl) was then added and incubated for 1 h to capture the immune complex. The beads were collected and washed four times in lysis buffer for 10 min and then once in LiCl buffer [ 
RESULTS
The expression of Bhlhe40 is significantly activated during terminal differentiation
To clarify whether Bhlhe40 regulates the expression of PGC-1α, and other members of the PGC-1 family, during myogenesis, we first examined the expression of PGC-1 family members, as well as P/CAF and Bhlhe40, in C2C12 myoblasts during their terminal myogenic differentiation by quantitative real-time RT-PCR. The expression level of PGC-1α and -1β increased significantly as cells differentiated terminally into MTs (Figure 1 ). Similar patterns were observed with the expression of Myog, MyoD, Bhlhe40 and P/CAF. Surprisingly, the expression of PRC was significantly reduced at CMB stage, but returned to the PMB stage level after serum withdrawal. The similar expression profile of PGC-1α and Bhlhe40 suggests that Bhlhe40 might regulate the expression of PGC-1α during terminal myogenesis.
Bhlhe40 binds to the E1-box of the PGC-1α promoter
Our previous results demonstrated that the E2-box was targeted by myogenic bHLH proteins, and bioinformatics predicted that the E1-box was targeted by Bhlhe40 [21] . To verify whether Bhlhe40 targeted the E1-box by direct binding, we employed EMSA to examine the binding of Bhlhe40 protein to the wild-type and mutant PGC-1α DNA core promoters shown in Figure 2(A) . As predicted, bacterially expressed MBP-Bhlhe40 bound both wild-type and mutant2 (lacking only the E-2 box) PGC-1α core promoter ( Figures 2B, lane 6, and 2C, lanes 3 and 9) . The binding of GST-MyoD and GST-Myog to wild-type PGC-1α core promoter was also examined ( Figure 2B, lanes 3 and 4) . When Bhlhe40 and MyoD were included in the same binding reaction, a heterodimer and a higher-order complex were observed ( Figure 2D , lanes 9-11) and both of them could be super-shifted by antibodies against MyoD and MBP ( Figure 2D, lanes 12 and 13) . These results suggest that Bhlhe40 and MyoD can simultaneously bind to the E1-and E2-boxes respectively.
Bhlhe40 represses MyoD-mediated activation of PGC-1α and PRC promoter
We further investigated whether the PGC-1α promoter activity is affected by Bhlhe40 binding to the E1-box. As PGC-1 family members are all expressed in skeletal muscle (Figure 1 ), and they share overlapping functions in metabolism [33, 34] , it was interesting to know whether PGC-1β and PRC are also regulated by MRFs in a similar manner to PGC-1α. Therefore, promoter constructs from these genes, driving a luciferase reporter gene, were transiently transfected into 10T1/2 cells to examine their regulation by MyoD and Bhlhe40. We found that the promoters of PGC-1α and PRC were activated by MyoD and this activation was compromised when Bhlhe40 was included (Figure 3 ). To our surprise, the PGC-1β promoter was not activated by MyoD and thus not affected by Bhlhe40. Bhlhe40 alone also had little or no effect on the promoters. These results suggest that Bhlhe40 may serve as a specific repressor of MRFs by interfering with their activation of myogenic genes. The binding sites of MyoD and Bhlhe40 on the PRC promoter will need to be further defined.
Bhlhe40 represses MyoD-mediated activation of myogenic genes
We next investigated whether Bhlhe40 serves as a general antagonist of MRFs, or only of certain MRFs target genes. Therefore the effect of Bhlhe40 co-expression was examined on the promoters of MCK (muscle creatin kinase), Myog, p21Cip1 and the 4RE-TK promoter construct. Co-expression of Bhlhe40 generally reduced MyoD-mediated activation, but only by a statistically significant margin for MCK, Myog and 4RE-TK ( Figure 4A ). These results suggest that Bhlhe40 serves as a general antagonist of MRFs, but that a subset of myogenic genes, such as Myog, are more sensitive to the presence of Bhlhe40 than others. The effect of Bhlhe40 on Mef2c (myocyte enhancer factor 2C)-mediated activation was 3 and 8) on the wild-type probe. Antibody (0.5 μg) against MyoD and MBP was included in lanes 12 and 13 respectively to determine the protein identity included in the complex. The relative mobility of the complex formed by MyoD, Bhlhe40 or both is indicated.
also examined and we found that Bhlhe40 had no effect on Mef2c-mediated transcriptional activation ( Figure 4B ).
P/CAF rescues Bhlhe40-mediated repression of MyoD transactivation
As MyoD plays critical roles in myogenic terminal differentiation, the significant up-regulation of Bhlhe40 upon terminal differentiation (Figure 1 ) will certainly inhibit terminal differentiation if other measures are not employed to counteract the activity of Bhlhe40. We speculated that key co-activators of MyoD, such as p300/CBP and P/CAF, may co-activate MyoD transactivation by relieving Bhlhe40-mediated repression. To test this speculation, P/CAF and CBP were co-transfected with both MyoD and Bhlhe40, and the PGC-1α promoter construct. Co-transfection of P/CAF significantly increased MyoD-mediated activation of PGC-1α promoter and also relieved Bhlhe40-mediated repression in a dose-dependent manner (Figures 5A and 5B) . In contrast The promoters of the PGC-1 family were co-transfected with either Bhlhe40 or MyoD expression vectors into 10T1/2 cells to examine their regulation by MyoD and Bhlhe40. Cells were harvested 48 h after transfection for determining their luciferase activity. Luciferase activity of each reporter construct in the absence of MyoD and Bhlhe40 was set as 1-fold activation. Results are the means of four independent assays. **P < 0.01 compared with the activity of GFP only. The significance of Bhlhe40-mediated repression of MyoD transactivation was also examined by a t test and shown as P-value above each bar.
with the effect with P/CAF, co-transfection with CBP had no effect on Bhlhe40-mediated repression of MyoD transactivation ( Figure 5C ). These results explain why terminal differentiation can still proceed in the presence of abundant Bhlhe40, as the expression of P/CAF is also concomitantly increased upon terminal differentiation (Figure 1 ). This is the first time P/CAF both co-activating with MyoD and suppressing repression by Bhlhe40 has been observed.
To further elucidate the physiological relevance of P/CAFmediated relief of repression, we examined the relative expression level of PGC-1α, P/CAF and Bhlhe40 in gastrocnemius (a fasttwitch muscle) and soleus (a slow-twitch muscle) fibres. As with the results observed during terminal differentiation in vitro, the expression level of these three genes increased in parallel with one another in soleus muscle ( Figure 5D ). We used the increased expression of slow-twitch type MHC (myosin heavy chain), called MHC-slow, in soleus as a positive control. These results suggest that the rescue of Bhlhe40-mediated repression of MyoD transactivation by P/CAF could play a critical role in the expression of MyoD target genes, especially PGC-1α, during both myogenic differentiation and fibre-type specification.
Bhlhe40 interacts with P/CAF in vitro
To elucidate the mechanism by which P/CAF rescued Bhlhe40-mediated repression of MyoD transactivation, we studied their interaction in vitro by using GST-MyoD and MBP-Bhlhe40 fusion proteins to pulldown [
35 S]-labelled proteins. In sharp contrast to its strong interaction with Mef2c and E12 (transcription factor 3, also known as Tcf3), a bHLH protein that forms a heterodimer with MyoD in vivo [35] , GST-MyoD interacted with [
35 S]-labelled Bhlhe40 only very weakly ( Figure 6A ). Similar results were also observed when MBP-Bhlhe40 was used to pulldown [ 35 S]-labelled MyoD ( Figure 6B, lane 3) . However, significant interaction between MBP-Bhlhe40 and [
35 S]-labelled P/CAF was observed ( Figure 6B ), implying that they might interact with each other in vivo. In order to determine whether the P/CAF-Bhlhe40 interaction affects the interaction between P/CAF and MyoD we included MBP-Bhlhe40, or MBP alone as a negative control, in the binding assay. We found that addition of MBP to the pulldown assay slightly enhanced the interaction between MyoD and P/CAF. (Figure 6C, lanes 7-9) . In contrast, this interaction was reduced significantly when MBP-Bhlhe40 was included ( Figure 6C, lanes 4-6) . These results suggest that Bhlhe40 may repress MyoD-mediated transactivation by blocking its interaction with co-activators, such as P/CAF.
Bhlhe40 binds to PGC-1α and Myog promoters in vivo
To further investigate complex formation between Bhlhe40 and MRFs on myogenic gene promoters in vivo, antibodies against MyoD, Myog and Bhlhe40 were used to pulldown their complex with chromatin in a ChIP assay. We found that all three factors bound significantly to the promoters of PGC-1α and Myog during the process of terminal differentiation (Figure 7) . However, the binding of Bhlhe40 to these two promoters in cells of CMB stage ( Figure 7A ) was significantly higher (P < 0.01) than those in cells at DM1 and DM5 ( Figures 7B and 7C ). These observations suggest that Bhlhe40 binds to and forms complexes with MRFs on the promoters of myogenic genes in vivo to regulate the activity of MRFs during terminal differentiation. The stronger binding in cells of CMB stage implies that it might function in preventing premature initiation of the differentiation programme by antagonizing MRF activity at this stage.
DISCUSSION
Myogenic terminal differentiation is critically regulated by MRFs. So it is intriguing to know that Bhlhe40 can repress MRF-mediated transactivation of myogenic genes while its expression increased significantly during terminal differentiation. The present study suggests that, to overcome the negative effect of Bhlhe40 expression on MyoD transactivation, P/CAF is induced to relieve MyoD from Bhlhe40-mediated repression. However, this gives rise to an interesting question, namely what is the purpose for the increased expression of Bhlhe40 in terminally differentiated cells? Intriguingly, previously reported observations show that Bhlhe40-null mice have normal skeletal muscle development, but impaired muscle regeneration after damage [27] . The Notch signalling pathway is also enhanced in Bhlhe40-null mice and this results in increased proliferation and defective differentiation of muscle cells. Both these phenomena can be rescued either by Bhlhe40 over-expression or inhibition of Notch signalling [27] . Therefore, Bhlhe40 in terminally differentiated cells seems to play critical roles in the adult muscle regeneration and/or replenishment by antagonizing Notch signalling. Further studies have also suggested that activation of the Notch pathway is inhibitory to myogenic differentiation in other systems [36] [37] [38] . These studies, together with the results in the present study, suggest that the increase in Bhlhe40 expression is possibly necessary to antagonize Notch signalling, thereby allowing terminal differentiation to proceed. Thus, Bhlhe40 and P/CAF seem to form a crosstalk bridge between MRFs and the Notch signalling pathway to ensure terminal myogenic differentiation proceeds. It will be interesting to know whether similar mechanisms operate in the regulation of cell differentiation in other lineages. P/CAF has been shown to play a critical role during myogenesis by functioning as a co-activator of MyoD [9, 10] . The P/CAF HAT activity is required for MyoD-mediated activation of Myog and p21Cip1 expression [6] . CBP/p300 is also required for myogenesis and its HAT activity is essential for MyoD-mediated activation of MHC and MCK expression [6, 8] . In the present paper, we found that Bhlhe40 antagonized MyoD transactivation of PGC-1α, MCK and Myog, but not that of p21Cip1. Although both CBP/p300 and P/CAF co-activated MyoD transactivation, only P/CAF was found to rescue the Bhlhe40-mediated antagonism of MyoD transactivation of the PGC-1α promoter. These observations imply that Bhlhe40 may repress MyoD transactivation by blocking the recruitment of the specific HAT containing co-activators required by different target genes. Thus, it is of interest to know whether P/CAF can also restore expression of other Bhlhe40-repressed genes such as Myog, which requires P/CAF HAT activity for its expression, and/or genes such as MCK, which require the CBP HAT activity. We are currently investigating these questions.
In adult muscle, PGC-1α is preferentially expressed in slowtwitch fibres, such as soleus, which are much higher in mitochondria content and are more dependent on oxidative metabolism than fast-twitch fibres, such as gastrocnemius [14] . This differential expression of PGC-1α is important to the development of slow-twitch fibres; over-expression of PGC-1α in the putative fast-twitch fibres can convert them into slow-twitch fibres [14] . Similar differential expression patterns for Bhlhe40 and P/CAF in soleus and gastrocnemius muscles were also observed in the present study ( Figure 5 ).
The concomitant up-regulation of PGC-1α, Bhlhe40 and P/CAF suggests that P/CAF-mediated relief of Bhlhe40 repression on MRF transactivation might also be important to the fibre-type specification or switch. It has been shown that Myog expression is enriched in the slow-twitch fibres [39] , and our results suggest that the Myog promoter is also subjected to the regulation by Bhlhe40. Thus it will be interesting to know whether the activation of other slow-twitch specific genes, such as Tnni1 (troponin I, skeletal, slow 1), by Myog is also targeted by Bhlhe40 and P/CAF.
PGC-1α and Bhlhe40 share very similar expression patterns among various human tissues and they are both highly activated in heart, skeletal muscle and kidney [13, 27, 28] . As MRFs are muscle-specific genes, and the expression of PGC-1α outside skeletal muscle is therefore not regulated by MRFs, it is possible that the physiological significance of Bhlhe40-mediated repression of PGC-1α lies outside skeletal muscle. To verify the significance of this repression in other tissues, activation of PGC-1α by other transcription factors, along with Bhlhe40, should be examined. Apart from MRFs, it is known the expression of PGC-1α is also regulated by other transcription factors, including MEF2, FOXO1 (forkhead box protein O1) and CREB, in muscle and other tissues [40] [41] [42] . MEF2 activates PGC-1α expression by binding to the upstream enhancer sites [40] and this activation is not affected by Bhlhe40 in the present study. FOXO1 is a forkhead transcription factor that binds to the IRES (insulin response elements) on the PGC-1α promoter to activate its expression [41] . CREB binds to the cAMP-response elements close to the transcription initiation sites to activate PGC-1α expression [42] . Further studies are required to examine if Bhlhe40 can repress the activation of PGC-1α mediated by CREB, FOXO1 and other transcription factors, either by the same mechanism or by other means.
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